Crystallization (Comment) | Organism |
---|---|
hanging-drop vapor-diffusion method, crystal structure of plasmepsin 4 bound to the allophenylnorstatine-based compound KNI-764 at 3.3 A resolution. The PmPM4inhibitor complex crystallized in the ortho-rhombic space group P2(1)2(1)2, with unit-cell parameters a = 95.9 A, b = 112.6 A, c = 90.4 A, with two molecules in the asymmetric unit | Plasmodium malariae |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(4R)-3-[(2S,3S)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)carbonyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-N-(2-methylbenzyl)-1,3-thiazolidine-4-carboxamide | - |
Plasmodium malariae | |
(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)carbonyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | - |
Plasmodium malariae | |
N-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(cyclohexa-1,3-dien-1-yloxy)acetyl]-L-valinamide | - |
Plasmodium malariae | |
N-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(isoquinolin-5-yloxy)acetyl]-L-valinamide | - |
Plasmodium malariae | |
N1-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(isoquinolin-5-yloxy)acetyl]-L-aspartamide | - |
Plasmodium malariae |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
vacuole | food vacuole | Plasmodium malariae | 5773 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Plasmodium malariae | - |
- |
- |
Purification (Comment) | Organism |
---|---|
- |
Plasmodium malariae |
Synonyms | Comment | Organism |
---|---|---|
plasmepsin 4 | - |
Plasmodium malariae |
PmPM4 | - |
Plasmodium malariae |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.000025 | - |
N-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(isoquinolin-5-yloxy)acetyl]-L-valinamide | - |
Plasmodium malariae | |
0.00011 | - |
(4R)-3-[(2S,3S)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)carbonyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-N-(2-methylbenzyl)-1,3-thiazolidine-4-carboxamide | - |
Plasmodium malariae | |
0.00016 | - |
N-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(cyclohexa-1,3-dien-1-yloxy)acetyl]-L-valinamide | - |
Plasmodium malariae | |
0.003 | - |
N-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(isoquinolin-5-yloxy)acetyl]-L-valinamide | - |
Plasmodium malariae | |
0.003 | - |
(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)carbonyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | - |
Plasmodium malariae | |
0.0071 | - |
N1-[(1S,2S)-1-benzyl-3-[(4R)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl]-N2-[(isoquinolin-5-yloxy)acetyl]-L-aspartamide | - |
Plasmodium malariae |